Clinical trial NCT05339958: Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hair Thinning
Keywords: Nutraceutical
Supplement
Lead sponsor: Nutraceutical Wellness Inc.
Sponsor class: INDUSTRY
First posted: 2022-04-21
Enrollment: 112
Sex: MALE
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a 6-month, multi-center, randomized, double-blind, placebo-controlled study in adult male subjects with self-perceived hair thinning. Subjects will be randomly assigned to either Nutrafol® Men hair growth supplement or placebo.
Primary purpose: PREVENTION

Brief summary: The objective of this study is to assess the effectiveness and safety of a novel dietary supplement containing botanical ingredients for hair thinning in men over the course of six months of continuous daily usage.

Detailed description: Hair thinning is a common condition affecting both men and women that is more recently understood to be the result of multiple causes. Although it is generally a benign condition, hair thinning can have a significant, detrimental impact on self-esteem, psychosocial functioning and the overall quality of life of affected individuals. It can also represent a substantial financial burden on individuals seeking treatment.

The objective of this randomized, double-blind, placebo-controlled study is to assess the effectiveness and safety of a novel dietary supplement containing botanical ingredients for hair thinning over the course of six months of continuous daily usage. The study supplement is scientifically formulated to specifically target the multiple underlying causes of hair thinning. In addition to the necessary vitamins, minerals, and proteins to support the nutritional needs of hair, it also contains clinically tested, standardized pharmaceutical-grade botanicals (substances obtained from plants) that target hormones, stress and inflammatory markers.

Eligibility criteria: Inclusion Criteria:

* Males between 21-55 years of age with self-perceived thinning
* Voluntarily sign and date an informed consent agreement and photo release form approved by the Institutional Review Board
* Clinically confirmed to have hair thinning or loss by the investigator or qualified sub-investigator via physical exam, including only subjects with male pattern hair loss with frontal and/or vertex patterns II, IIA, III, IIIv and IV using the Norwood classification of patterned hair loss in males.
* General good health, as determined by the Investigator or qualified sub-investigator
* Willing and able to attend all study visits and comply with the test product daily instructions.
* Willing to maintain the same hair style and same color for the duration of the study.
* Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
* Willing and able to cooperate with the requirements of the study.
* Able to complete and understand the various rating instruments.

Exclusion Criteria:

* Individuals who have experienced serious complications due to COVID-19 previously or during the study as determined by the investigator.
* Clinical diagnosis of hair loss disorder such as alopecia areata, or scarring forms of alopecia.
* Subjects with male pattern hair loss with frontal and/or vertex patterns I, IIIA, IVA, V, VA, VI, VII using the Norwood classification of patterned hair loss in males.
* Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
* Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), cuts and or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator or qualified sub-investigator, might put the subject at risk or interfere with the study conduct or evaluations.
* History of surgical correction of hair loss on the scalp (i.e. hair transplant).
* Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
* Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, progesterone, and bicalutamide) within 3 months prior to the Baseline Visit.
* History of burning, flaking, itching, and stinging of the scalp.
* History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
* A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator or qualified sub-investigator may interfere with the study treatment.
* A known history of unstable or chronic depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator or qualified sub-investigator.
* A known allergy to any of the ingredients in the investigational product.
* Utilization of low-level lasers for hair growth in the last three months.
* Any condition that the Investigator thinks may put the subject at risk or interfere with their participation in the study.
* Known history or recent blood work indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage \>20 cigarettes/day.
* Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.

Primary outcomes:
measure: Change in terminal hair counts
timeFrame: Day 180
Secondary outcomes:
measure: Proportion of subjects with ≥5% hair growth
timeFrame: Day 180
measure: Change in total, terminal and vellus and hair count
timeFrame: Day 180
measure: Change in mean hair width and mean inter-follicular distance
timeFrame: Day 180
measure: Change in terminal to vellus ratio
timeFrame: Day 180
measure: Change in mean number of hairs per follicular unit
timeFrame: Day 180
measure: Hair Shedding
timeFrame: Day 180
measure: Subject Assessments
timeFrame: Day 180
measure: Blinded Investigator Assessment
timeFrame: Day 180
measure: Compiled side effects
timeFrame: Day 180
Other outcomes:
Locations:
city: Manhattan Beach
country: United States
facility: Ablon Skin Institute and Research Center
state: California
city: San Diego
country: United States
facility: Therapeutic Clinical Research
state: California
Study officials:
References: